Main comparative features of the therapeutic products containing VWF only
| Characteristics . | Production method . | |
|---|---|---|
| Plasma fractionation . | Recombinant technology . | |
| Commercial name | Wilfactin/Willfact | Vonvendi/Veyvondi |
| Generic name | Human VWF | Vonicog alfa |
| Licensing | EMA | FDA and EMA |
| VWF HMWMs | Deficient | All present |
| Ultra-large VWF multimers | Absent | Present |
| VWF:RCo/FVIII:C, IU/dL, ratio | >60 | FVIII: only traces |
| Characteristics . | Production method . | |
|---|---|---|
| Plasma fractionation . | Recombinant technology . | |
| Commercial name | Wilfactin/Willfact | Vonvendi/Veyvondi |
| Generic name | Human VWF | Vonicog alfa |
| Licensing | EMA | FDA and EMA |
| VWF HMWMs | Deficient | All present |
| Ultra-large VWF multimers | Absent | Present |
| VWF:RCo/FVIII:C, IU/dL, ratio | >60 | FVIII: only traces |
EMA, European Medicines Agency; FDA, US Food and Drug Administration.